San Diego's Illumina will delay releasing its fourth quarter and year end 2011 financial results while its board of directors reviews a $5.7 billion hostile takeover bid by Swiss Pharmaceutical giant Roche.

Illumina, which makes gene mapping equipment, was slated to financial report results on Tuesday.

Now its board of directors is reviewing Roche... ...

Read the full story at San Diego Union-Tribune